Style | Citing Format |
---|---|
MLA | Davoodimoghaddam Z, et al.. "A Systematic Review and Meta-Analysis of Immune Checkpoint Therapy in Relapsed or Refractory Non-Hodgkin Lymphoma; a Friend or Foe?." Translational Oncology, vol. 30, no. , 2023, pp. -. |
APA | Davoodimoghaddam Z, Jafariraddani F, Noori M, Bashash D (2023). A Systematic Review and Meta-Analysis of Immune Checkpoint Therapy in Relapsed or Refractory Non-Hodgkin Lymphoma; a Friend or Foe?. Translational Oncology, 30(), -. |
Chicago | Davoodimoghaddam Z, Jafariraddani F, Noori M, Bashash D. "A Systematic Review and Meta-Analysis of Immune Checkpoint Therapy in Relapsed or Refractory Non-Hodgkin Lymphoma; a Friend or Foe?." Translational Oncology 30, no. (2023): -. |
Harvard | Davoodimoghaddam Z et al. (2023) 'A Systematic Review and Meta-Analysis of Immune Checkpoint Therapy in Relapsed or Refractory Non-Hodgkin Lymphoma; a Friend or Foe?', Translational Oncology, 30(), pp. -. |
Vancouver | Davoodimoghaddam Z, Jafariraddani F, Noori M, Bashash D. A Systematic Review and Meta-Analysis of Immune Checkpoint Therapy in Relapsed or Refractory Non-Hodgkin Lymphoma; a Friend or Foe?. Translational Oncology. 2023;30():-. |
BibTex | @article{ author = {Davoodimoghaddam Z and Jafariraddani F and Noori M and Bashash D}, title = {A Systematic Review and Meta-Analysis of Immune Checkpoint Therapy in Relapsed or Refractory Non-Hodgkin Lymphoma; a Friend or Foe?}, journal = {Translational Oncology}, volume = {30}, number = {}, pages = {-}, year = {2023} } |
RIS | TY - JOUR AU - Davoodimoghaddam Z AU - Jafariraddani F AU - Noori M AU - Bashash D TI - A Systematic Review and Meta-Analysis of Immune Checkpoint Therapy in Relapsed or Refractory Non-Hodgkin Lymphoma; a Friend or Foe? JO - Translational Oncology VL - 30 IS - SP - EP - PY - 2023 ER - |